OmniAb, Inc.
Eric Vajda has over two decades of experience in the pharmaceutical industry. Eric started their career at Bayer Corp. in 1999 as a Sr. Research Scientist. In 2002, they joined Ligand Pharmaceuticals as a Sr. Research Investigator and gradually moved up to become the Director of Pharmacology and then the Sr. Director of Preclinical Research and Development. In 2016, they were promoted to Vice President at Ligand Pharmaceuticals. Currently, they hold the position of Vice President of Pre-clinical Research and Development at OmniAb, Inc.
Eric Vajda holds a Bachelor of Science degree from Yale University. Eric'sfield of study during their time at Yale is not specified. Eric further pursued their education at the University of Utah, where they earned a Ph.D. in Bioengineering and Biomedical Engineering. No specific start or end years are provided for either of their educational experiences.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.